AC 0682
Alternative Names: AC-0682; AC682Latest Information Update: 24 Apr 2024
At a glance
- Originator Accutar Biotechnology
- Class Antineoplastics
- Mechanism of Action Estrogen receptor degraders
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase I HER2 negative breast cancer
Most Recent Events
- 11 Apr 2024 Accutar Biotechnology terminates phase I trial HER2 negative breast cancer (Late-stage disease, Metastatic disease) in USA since the sponsor's development strategy was adjusted(PO) (NCT05080842)
- 28 Sep 2023 Accutar Biotechnology terminates a phase I trial for HER2 negative breast cancer (Late stage disease, Metastatic disease, Second line therapy or greater) in China (PO), since the sponsor's development strategy was adjusted (NCT05489679)
- 12 Oct 2022 prior to Oct 2022, Phase-I clinical trials in HER2 negative breast cancer (Metastatic disease, Late-stage disease, Second line therapy or greater) in China (PO)